KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Finished Goods (2016 - 2025)

Acadia Pharmaceuticals has reported Finished Goods over the past 10 years, most recently at $26.0 million for Q4 2025.

  • Quarterly results put Finished Goods at $26.0 million for Q4 2025, up 26.84% from a year ago — trailing twelve months through Dec 2025 was $26.0 million (up 26.84% YoY), and the annual figure for FY2025 was $26.0 million, up 26.84%.
  • Finished Goods for Q4 2025 was $26.0 million at Acadia Pharmaceuticals, up from $25.0 million in the prior quarter.
  • Over the last five years, Finished Goods for ACAD hit a ceiling of $26.0 million in Q4 2025 and a floor of $947000.0 in Q1 2021.
  • Median Finished Goods over the past 5 years was $3.5 million (2021), compared with a mean of $9.5 million.
  • Biggest five-year swings in Finished Goods: tumbled 60.92% in 2021 and later soared 758.53% in 2024.
  • Acadia Pharmaceuticals' Finished Goods stood at $1.1 million in 2021, then surged by 72.89% to $1.9 million in 2022, then skyrocketed by 159.66% to $5.0 million in 2023, then surged by 309.14% to $20.5 million in 2024, then increased by 26.84% to $26.0 million in 2025.
  • The last three reported values for Finished Goods were $26.0 million (Q4 2025), $25.0 million (Q3 2025), and $23.4 million (Q2 2025) per Business Quant data.